Similar articles

• Choice of treatment in operable lung cancer.

  Belcher JR, Caplin M. Belcher JR, et al. Br Med J. 1979 May 5;1(6172):1212. doi: 10.1136/bmj.1.6172.1212. Br Med J. 1979. PMID: 445006 Free PMC article. No abstract available.
• Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.

  Yang KL, Chang YC, Ko HL, Chi MS, Wang HE, Hsu PS, Lin CC, Yeh DY, Kao SJ, Jiang JS, Chi KH. Yang KL, et al. Clin Lung Cancer. 2016 Nov;17(6):550-557. doi: 10.1016/j.cllc.2016.05.013. Epub 2016 Jun 8. Clin Lung Cancer. 2016. PMID: 27378175 Clinical Trial.
• [Stereotactic Ablative Aadiotherapy
--A Better Choice for Operable Stage I Non-small Cell Lung Cancer?].

  Yuan D, Song Y. Yuan D, et al. Zhongguo Fei Ai Za Zhi. 2015 Jun;18(6):325-7. doi: 10.3779/j.issn.1009-3419.2015.06.01. Zhongguo Fei Ai Za Zhi. 2015. PMID: 26104886 Free PMC article. Chinese. No abstract available.
• [Current treatment concepts of lung cancer].

  Kaiser F, Engelhardt M, Rawluk J, Mertelsmann R, Passlick B, Wäsch R. Kaiser F, et al. Dtsch Med Wochenschr. 2011 Sep;136(38):1901-6. doi: 10.1055/s-0031-1286361. Epub 2011 Sep 13. Dtsch Med Wochenschr. 2011. PMID: 21915805 Review. German.
• The lung cancer paradox: time for action.

  Rintoul RC, Sethi T. Rintoul RC, et al. Thorax. 2002 Oct;57 Suppl 2(Suppl 2):II57-II63. Thorax. 2002. PMID: 12364713 Free PMC article. Review. No abstract available.